Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNXH76
|
|||
| Drug Name |
Eptacog beta
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1] | |
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1/2 | [1] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1/2 | [1] | ||
| Company |
Hema Biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thioredoxin reductase (PRDX5) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health. | |||
| REF 2 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.